Qiang Wei

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 11

Top Topics

Radical Prostatectomy

Prostate Cancer

Top Venues

Clinical and translational medicine

Nanoscale advances

Cell death discovery

This page only lists publications with an associated author ORCID identifier.

Publications

Haozhe Zhang, Yi Zhou, Yating Feng, Wenli Hou, Yafei Chen, Zengzhen Xing, Yifan Zhang, Qiang Wei, Yu Yin, Ju Guo, Hailiang Hu
Cyclin-dependent kinase 12 deficiency reprogrammes cellular metabolism to alleviate ferroptosis potential and promote the progression of castration-resistant prostate cancer. Clinical and translational medicine 14 (5) (2024)
Haozhe Zhang, Yi Zhou, Yating Feng, Wenli Hou, Yafei Chen, Zengzhen Xing, Yifan Zhang, Qiang Wei, Yu Yin, Ju Guo, Hailiang Hu
Cyclin-dependent kinase 12 deficiency reprogrammes cellular metabolism to alleviate ferroptosis potential and promote the progression of castration-resistant prostate cancer. Clinical and translational medicine 14 (5) (2024)
Haozhe Zhang, Yi Zhou, Yating Feng, Wenli Hou, Yafei Chen, Zengzhen Xing, Yifan Zhang, Qiang Wei, Yu Yin, Ju Guo, Hailiang Hu
Cyclin-dependent kinase 12 deficiency reprogrammes cellular metabolism to alleviate ferroptosis potential and promote the progression of castration-resistant prostate cancer. Clinical and translational medicine 14 (5) (2024)
Haozhe Zhang, Yi Zhou, Yating Feng, Wenli Hou, Yafei Chen, Zengzhen Xing, Yifan Zhang, Qiang Wei, Yu Yin, Ju Guo, Hailiang Hu
Cyclin-dependent kinase 12 deficiency reprogrammes cellular metabolism to alleviate ferroptosis potential and promote the progression of castration-resistant prostate cancer. Clinical and translational medicine 14 (5) (2024)
Yingkai Hong, Wenli Hou, Dehua Ou, Mingen Lin, Mayao Luo, Qiang Wei
Liposome-coated nanoparticle triggers prostate cancer ferroptosis through synergetic chemodynamic-gas therapy. Nanoscale advances 6 (2) (2023)
Yingkai Hong, Wenli Hou, Dehua Ou, Mingen Lin, Mayao Luo, Qiang Wei
Liposome-coated nanoparticle triggers prostate cancer ferroptosis through synergetic chemodynamic-gas therapy. Nanoscale advances 6 (2) (2023)
Yifan Zhang, Yuanpeng Liao, Mayao Luo, Yuedian Ye, Zhuofan Xu, Wenli Hou, Ruiyu Liu, Qiliang Zhai, Shidong Lv, Qiang Wei
IU1 and enzalutamide combination yields synergistic effects on castration-resistant prostate cancer. The Prostate (2023)
Shidong Lv, Zeyu Wu, Mayao Luo, Yifan Zhang, Jianqiang Zhang, Laura E Pascal, Zhou Wang, Qiang Wei
Integrated analysis reveals FOXA1 and Ku70/Ku80 as targets of ivermectin in prostate cancer. Cell death & disease 13 (9) (2022)
Mayao Luo, Yifan Zhang, Zhuofan Xu, Chenwei Wu, Yuedian Ye, Rui Liu, Shidong Lv, Qiang Wei
Tautomycin and enzalutamide combination yields synergistic effects on castration-resistant prostate cancer. Cell death discovery 8 (1) (2022)
Haitian He, Jianhua Li, Mayao Luo, Qiang Wei
Inhibitory role of circRNA_100395 in the proliferation and metastasis of prostate cancer cells. The Journal of international medical research 49 (2) (2021)
Shidong Lv, Haoran Wen, Xiongwei Shan, Jianhua Li, Yaobin Wu, Xinpei Yu, Wenhua Huang, Qiang Wei
Loss of KMT2D induces prostate cancer ROS-mediated DNA damage by suppressing the enhancer activity and DNA binding of antioxidant transcription factor FOXO3. Epigenetics 14 (12) (2019)